Terns Pharmaceuticals Statistics
Share Statistics
Terns Pharmaceuticals has 84.94M shares outstanding. The number of shares has increased by 31.38% in one year.
| Shares Outstanding | 84.94M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.6% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 62.32M |
| Failed to Deliver (FTD) Shares | 612 |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 6.20M, so 7.3% of the outstanding shares have been sold short.
| Short Interest | 6.20M |
| Short % of Shares Out | 7.3% |
| Short % of Float | 9.96% |
| Short Ratio (days to cover) | 3.46 |
Valuation Ratios
The PE ratio is -5.13 and the forward PE ratio is -5.35.
| PE Ratio | -5.13 |
| Forward PE | -5.35 |
| PS Ratio | 0 |
| Forward PS | 161.9 |
| PB Ratio | 1.81 |
| P/FCF Ratio | -6.86 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Terns Pharmaceuticals Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 22.39, with a Debt / Equity ratio of 0.
| Current Ratio | 22.39 |
| Quick Ratio | 22.39 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.35% and return on capital (ROIC) is -40.17%.
| Return on Equity (ROE) | -0.35% |
| Return on Assets (ROA) | -0.34% |
| Return on Capital (ROIC) | -40.17% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.37M |
| Employee Count | 66 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 239.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -20.62% in the last 52 weeks. The beta is -0.33, so Terns Pharmaceuticals 's price volatility has been lower than the market average.
| Beta | -0.33 |
| 52-Week Price Change | -20.62% |
| 50-Day Moving Average | 6.22 |
| 200-Day Moving Average | 6.95 |
| Relative Strength Index (RSI) | 27.02 |
| Average Volume (20 Days) | 1.62M |
Income Statement
| Revenue | n/a |
| Gross Profit | -881.00K |
| Operating Income | -102.56M |
| Net Income | -90.21M |
| EBITDA | -102.27M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.27 |
Balance Sheet
The company has 79.93M in cash and 603.00K in debt, giving a net cash position of 79.32M.
| Cash & Cash Equivalents | 79.93M |
| Total Debt | 603.00K |
| Net Cash | 79.32M |
| Retained Earnings | -332.63M |
| Total Assets | 378.23M |
| Working Capital | 365.09M |
Cash Flow
In the last 12 months, operating cash flow was -67.39M and capital expenditures -52.00K, giving a free cash flow of -67.44M.
| Operating Cash Flow | -67.39M |
| Capital Expenditures | -52.00K |
| Free Cash Flow | -67.44M |
| FCF Per Share | -0.95 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TERN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -27.73% |
| FCF Yield | -17.36% |
Analyst Forecast
The average price target for TERN is $20, which is 336.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $20 |
| Price Target Difference | 336.7% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 19.95 |
| Piotroski F-Score | 3 |